{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,21]],"date-time":"2026-08-21T21:57:57Z","timestamp":1787349477775,"version":"build-2736575974"},"reference-count":19,"publisher":"MDPI AG","issue":"4","license":[{"start":{"date-parts":[[2017,12,11]],"date-time":"2017-12-11T00:00:00Z","timestamp":1512950400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Medical Sciences"],"abstract":"<jats:p>Aims and objectives: The cost of antibiotic therapy for the treatment of pneumonia in the inpatient paediatric population can have a major impact on the healthcare expenditure. We planned to assess the direct and indirect costs of diagnosis and medical treatment of paediatric patients with community acquired pneumonia who are hospitalized in a tertiary care hospital in India. Methods: 125 children with a diagnosis of pneumonia who were admitted to the inpatient department of a paediatric hospital receiving antibiotic treatment were observed. Data on clinical presentation and resources consumed were collected and the costs of pneumonia treatment were calculated. Descriptive statistics (mean \u00b1 standard deviation (SD)) were used to evaluate data regarding demographics, drugs prescribed and cost (direct and indirect cost). Multivariate regression analysis was used to find out predictors of direct and indirect cost. Results: Among all pneumonia admissions, mild-to-moderate pneumonia constitutes 76.8%, and 23.2% children were admitted with severe pneumonia; 105 children out of 125 (84%) were suffering from associated disorders along with pneumonia. The majority of antibiotics prescribed belonged to beta lactams (52%) followed by aminoglycosides (19%), macrolides (13%) and peptides (11%). Parenteral routes of administration were used in a majority of patients as compared to oral. The average cost per patient in management of pneumonia was 12245 \u00b1 593 INR ($187.34 \u00b1 9.07).<\/jats:p>","DOI":"10.3390\/medsci5040033","type":"journal-article","created":{"date-parts":[[2017,12,11]],"date-time":"2017-12-11T12:26:37Z","timestamp":1512995197000},"page":"33","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Pharmacoeconomic Analysis of Drugs Used in the Treatment of Pneumonia in Paediatric Population in a Tertiary Care Hospital in India\u2014A Cost-of-Illness Study"],"prefix":"10.3390","volume":"5","author":[{"given":"Lekha","family":"Saha","sequence":"first","affiliation":[{"name":"Department of Pharmacology, Post Graduate Institute of Medical Education &amp; Research (PGIMER), Chandigarh 160012, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sweta","family":"Kumari","sequence":"additional","affiliation":[{"name":"Department of Pharmacology, Post Graduate Institute of Medical Education &amp; Research (PGIMER), Chandigarh 160012, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pratibha","family":"Khosla","sequence":"additional","affiliation":[{"name":"Department of Pharmacology, Post Graduate Institute of Medical Education &amp; Research (PGIMER), Chandigarh 160012, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alka","family":"Rani","sequence":"additional","affiliation":[{"name":"Department of Pediatric Medicine, Post Graduate Institute of Medical Education &amp; Research (PGIMER), Chandigarh 160012, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sharonjeet","family":"Kaur","sequence":"additional","affiliation":[{"name":"Department of Pharmacology, Post Graduate Institute of Medical Education &amp; Research (PGIMER), Chandigarh 160012, India"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2017,12,11]]},"reference":[{"key":"ref_1","unstructured":"World Health Organization (2017, November 11). Available online: http:\/\/www.who.int\/ health-accounts\/ghed\/en\/."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"135","DOI":"10.3389\/fpubh.2015.00135","article-title":"BRIC\u2019s growing share of global health spending and their diverging pathways","volume":"3","author":"Jakovljevic","year":"2015","journal-title":"Front. Public Health"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"844","DOI":"10.1002\/hec.3406","article-title":"Evolving health expenditure landscape of the BRICS nations and projections to 2025","volume":"26","author":"Jakovljevic","year":"2017","journal-title":"Health Econ."},{"key":"ref_4","unstructured":"(2017). Global, regional, and national under-5 mortality, adult mortality, age\u2014Specific mortality, and life expectancy, 1970\u20132016: A systematic analysis for the Global Burden of Disease Study 2016. Lancet, 390, 1084\u20131150."},{"key":"ref_5","unstructured":"World Health Organization (2015). Pneumonia, WHO."},{"key":"ref_6","first-page":"895","article-title":"WHO Child Health Epidemiology Reference Group. Global estimate of the incidence of clinical pneumonia among children under five years of age","volume":"356","author":"Rudan","year":"2004","journal-title":"Bull. World Health Organ."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1590\/S1806-37132015000100007","article-title":"Community-acquired pneumonia: Economics of inpatient medical care vis-\u00e0-vis clinical severity","volume":"41","author":"Cupurdija","year":"2015","journal-title":"J. Bras. Pneumol."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"1048","DOI":"10.1016\/S0140-6736(06)69334-3","article-title":"Pneumonia: The leading killer of children","volume":"368","author":"Wardlaw","year":"2006","journal-title":"Lancet"},{"key":"ref_9","doi-asserted-by":"crossref","unstructured":"Jakovljevic, M., Groot, W., and Souliotis, K. (2016). Health care financing and affordability in the emerging global markets. Front. Public Health.","DOI":"10.3389\/978-2-88919-837-5"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"610","DOI":"10.1183\/09031936.04.00076704","article-title":"A population-based study of the costs of care for community-acquired pneumonia","volume":"23","author":"Bartolome","year":"2004","journal-title":"Eur. Respir. J."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"2148","DOI":"10.1378\/chest.124.6.2148","article-title":"Cost and incidence of social co morbidities in low-risk patients with community acquired pneumonia admitted to a public hospital","volume":"124","author":"Goss","year":"2003","journal-title":"Chest"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"1213","DOI":"10.1542\/peds.2004-1285","article-title":"Community-acquired pneumonia in children: Quantifying the burden on patients and their families including decrease in quality of life","volume":"115","author":"Shoham","year":"2005","journal-title":"Pediatrics"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1016\/j.amjmed.2007.04.023","article-title":"Efficacy of short-course antibiotic regimens for community-acquired pneumonia: A meta-analysis","volume":"120","author":"Li","year":"2007","journal-title":"Am. J. Med."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1097\/QCO.0b013e3280555072","article-title":"How long should we treat community-acquired pneumonia?","volume":"20","author":"Scalera","year":"2007","journal-title":"Curr. Opin. Infect. Dis."},{"key":"ref_15","first-page":"827","article-title":"Cost of medicines and their affordability in private pharmacies in Delhi (India)","volume":"136","author":"Roy","year":"2012","journal-title":"Indian J. Med. Res."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1016\/S2213-2600(17)30293-X","article-title":"Global, regional, and national deaths, prevalence, disability-adjusted life years, and years lived with disability for chronic obstructive pulmonary disease and asthma, 1990\u20132015: A systematic analysis for the Global burden of Disease study 2015","volume":"5","author":"Sariano","year":"2017","journal-title":"Lancet Respir Med."},{"key":"ref_17","doi-asserted-by":"crossref","unstructured":"Lorgelly, P.K., Atkinson, M., Lakhanpaul, M., Smyth, A.R., Vyas, H., Weston, V., and Stephenson, T. (2009). Oral versus IV antibiotics for CAP in children: A cost minimisation analysis. ERJ Express.","DOI":"10.1183\/09031936.00087209"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"161","DOI":"10.7175\/fe.v14i4.676","article-title":"Direct medical costs of COPD diagnosis and treatment, Eastern vs. Western European country\u2014Examples of Serbia and Belgium","volume":"14","author":"Jakovljevic","year":"2013","journal-title":"Farmeconomia Health Econ. Ther. Pathw."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1046\/j.1365-2753.2002.00351.x","article-title":"Clinical and economic outcomes of pneumonia in children: A longitudinal observational study in an Italian paediatric hospital","volume":"8","author":"Ciommo","year":"2002","journal-title":"J. Eval. Clin. Pract."}],"container-title":["Medical Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2076-3271\/5\/4\/33\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T18:53:30Z","timestamp":1760208810000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2076-3271\/5\/4\/33"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,12,11]]},"references-count":19,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2017,12]]}},"alternative-id":["medsci5040033"],"URL":"https:\/\/doi.org\/10.3390\/medsci5040033","relation":{},"ISSN":["2076-3271"],"issn-type":[{"value":"2076-3271","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,12,11]]}}}